CNSP · Cns Pharmaceuticals Inc

-

Please sign in to comment on CNSP

1 Comment

Admin

3 years, 7 months ago

CNS Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 17.4% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

CNS Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 18.9% to $-3M since the same quarter in the previous year.

Finally, its free cash flow grew by 41.8% to $-1M since the same quarter in the previous year.

Based on the above factors, CNS Pharmaceuticals, Inc gets an overall score of 2/5.

Industry	Biotechnology
Sector	Healthcare
ISIN	US18978H1023
CurrencyCode	USD
Exchange	NASDAQ

Dividend Yield	0.0%
Beta	1.19
Market Cap	2M
Target Price	10
PE Ratio	None

ABOUT

Cns Pharmaceuticals Inc

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based in Houston, Texas.

CNSP · Cns Pharmaceuticals Inc

-

Cns Pharmaceuticals Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Cns Pharmaceuticals Inc using a moving average strategy